RT Journal Article
SR Electronic
T1 CanVasc consensus recommendations for the management of antineutrophil cytoplasm antibody-associated vasculitis: 2020 update
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP jrheum.200721
DO 10.3899/jrheum.200721
A1 Mendel, Arielle
A1 Ennis, Daniel
A1 Go, Ellen
A1 Bakowsky, Volodko
A1 Baldwin, Corisande
A1 Benseler, Susanne M.
A1 Cabral, David A.
A1 Carette, Simon
A1 Clements-Baker, Marie
A1 Clifford, Alison
A1 Cohen Tervaert, Jan Willem
A1 Cox, Gerard
A1 Dehghan, Natasha
A1 Dipchand, Christine
A1 Dhindsa, Navjot
A1 Famorca, Leilani
A1 Fifi-Mah, Aurore
A1 Garner, Stephanie
A1 Girard, Louis-Philippe
A1 Lessard, Clode
A1 Liang, Patrick
A1 Noone, Damien
A1 Makhzoum, Jean-Paul
A1 Milman, Nataliya
A1 Pineau, Christian A.
A1 Reich, Heather N.
A1 Rhéaume, Maxime
A1 Robinson, David B.
A1 Rumsey, Dax G.
A1 Towheed, Tanveer E.
A1 Trudeau, Judith
A1 Twilt, Marinka
A1 Yacyshyn, Elaine
A1 Yeung, Rae
A1 Barra, Lillian
A1 Khalidi, Nader
A1 Pagnoux, Christian
YR 2020
UL http://www.jrheum.org/content/early/2020/09/10/jrheum.200721.abstract
AB Objective In 2015, the Canadian Vasculitis Research Network (CanVasc) created recommendations for the management of antineutrophil cytoplasm antibody (ANCA)-associated vasculitides (AAV) in Canada. The current update aimed to revise existing recommendations and create additional recommendations, as needed, based on a review of new available evidence. Methods A needs assessment survey of CanVasc members informed questions for an updated systematic literature review (publications spanning May 2014-September 2019) using Medline, Embase, and Cochrane. New and revised recommendations were developed and categorized according to the level of evidence and strength of each recommendation. The CanVasc working group used a two-step modified Delphi procedure to reach >80% consensus on the inclusion, wording and grading of each new and revised recommendation. Results Eleven new and 16 revised recommendations were created, and 12 original (2015) recommendations were retained. New and revised recommendations are discussed in detail within this document. Five original recommendations were removed, of which 4 were incorporated into the explanatory text. The supplementary appendix for practical use was revised to reflect the updated recommendations. Conclusion The 2020 updated recommendations provide rheumatologists, nephrologists, and other specialists caring for patients with AAV in Canada with new management guidance, based on current evidence and consensus from Canadian experts.